Clinical trial
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate…
NCT00046826 · Nuvance Health, Other · Completed
Key facts
| NCT number | NCT00046826 |
|---|---|
| Title | Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy |
| Official title | A Phase II Clinical Trial of Taxotere, Emcyt and Thalidomide (TET) for the Treatment of Hormone-Refractory Prostate Cancer |
| Lead sponsor | Nuvance Health, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, estramustine phosphate sodium, thalidomide |
| Start date | Sep 1, 2001 |
| Primary completion | Jun 1, 2007 |
| Completion | Oct 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: